Total item
Cart Subtotal
$0.00 Details
AP26113 is an orally-available, potent, and selective inhibitor of ALK with a potency of 0.62 nM against wild-type and activity against a wide range of mutants, including the crizotinib-resistant L1196M line. In a panel of EML4-ALK or NPM-ALK-positive cell lines, AP26113 has IC50 values of 4-31 nM. [1][2]
AP26113 is effective against sensitive and resistant H3122 cells, reducing cell growth, suppressing ALK phosphorylation, and inducing apoptosis. In Ba/F3 cells expressing native or mutant EML4-ALK, AP26113 was active at IC50s of 10 and 24 nM, respectively. [3]
Targets
| Target | Value |
|---|---|
| ALK | IC50: 0.62nM |
| FER | IC50: 1.3nM |
| ROS/ROS1 | IC50: 1.9nM |
| FLT3 | IC50: 2.1nM |
| FES/FPS | IC50: 3.4nM |
| FAK/PTK2 | IC50: 3.8nM |
| BRK | IC50: 4.1nM |
| STK22D | IC50: 4.3nM |
| Chk2 | IC50: 6.5nM |
| RSK2 | IC50: 13nM |
| TYK/LTK | IC50: 13nM |
| YES | IC50: 19nM |
| PYK2 | IC50: 24nM |
| ErbB4 | IC50: 27nM |
| CLK1 | IC50: 29nM |
| CaMKIId | IC50: 29nM |
| Chk1 | IC50: 30nM |
| RSK1 | IC50: 30nM |
| RSK4 | IC50: 42nM |
| IRR/INSRR | IC50: 45nM |
| IGF-1R | IC50: 46nM |
| ARK5 | IC50: 47nM |
| CaMKIIg | IC50: 48nM |
| LRRK2 | IC50: 51nM |
| FRK | IC50: 52nM |
| FLT4 | IC50: 58nM |
| RET | IC50: 65nM |
| CaMKK2 | IC50: 83nM |
| MARK2 | IC50: 94nM |
| PKCnu | IC50: 95nM |
| PHKg2 | IC50: 108nM |
| LOK/STK10 | IC50: 123nM |
| BRSK2 | IC50: 125nM |
| MARK3 | IC50: 127nM |
| MARK1 | IC50: 127nM |
| FGFR1 | IC50: 128nM |
| EGFR | IC50: 129nM |
| BLK | IC50: 136nM |
| TSSK2 | IC50: 138nM |
| AuroraA | IC50: 146nM |
| JAK2 | IC50: 154nM |
| FGFR4 | IC50: 181nM |
| PKCmu/PKD1 | IC50: 197nM |
| Fyn | IC50: 198nM |
| Hck | IC50: 198nM |
| MLK1/MAP3K9 | IC50: 218nM |
| FGFR2 | IC50: 228nM |
| CLK2 | IC50: 240nM |
| Lyn | IC50: 241nM |
| PKD2/PRKD2 | IC50: 285nM |
| c-Src | IC50: 329nM |
| BRSK1 | IC50: 338nM |
| FGFR3 | IC50: 358nM |
| Fms | IC50: 358nM |
| Insulin Receptor | IC50: 395nM |
| SIK2/SNF1LK2/QIK | IC50: 466nM |
| FGR | IC50: 491nM |
| TAOK1 | IC50: 492nM |
| Abl1 | IC50: 500nM |
| LCK | IC50: 512nM |
| PLK1 | IC50: 611nM |
| BTK | IC50: 673nM[null] |
| In vitro (25°C) | DMSO | 45 mg/mL (85.06 mM) | |
| Water | <1 mg/mL (<1 mM) | ||
| Ethanol | 106 mg/mL (200.37 mM) | ||
| In vivo | NMP/polyethylene glycol 300 (10/90, v/v) | 30 mg/mL | |
|
* <1 mg/ml means slightly soluble or insoluble. * Please note that Adooq tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations. |
|||
| Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 0.1 mM | 18.9 mL | 94.52 mL | 189.03 mL |
| 0.5 mM | 3.78 mL | 18.9 mL | 37.81 mL |
| 1 mM | 1.89 mL | 9.45 mL | 18.9 mL |
| 5 mM | 0.38 mL | 1.89 mL | 3.78 mL |
*The above data is based on the productmolecular weight 529.01. Batch specific molecular weights may vary from batch to batch due to solvent of hydration, which will affect the solvent volumes required to prepare stock solutions.
1. Shiao et al., Anaplastic Lymphoma Kinase (ALK) Inhibitors: New Cancer Breakthroughs for Lung Cancer, J. Cancer. Res. Pract. 2011, 27(4), 143-156.
2. Rivera et al., Efficacy and pharmacodynamic analysis of AP26113, a potent and selective orally active inhibitor of Anaplastic Lymphoma Kinase (ALK). Cancer Res. 2010, 70(8), Suppl 1., AACR 101st Annual Meeting 2010.
3. Katayama et al., Therapeutic strategies to overcome crizotinib resistance in non-small cell lung cancers harboring the fusion oncogene EML4-ALK. Proc. Natl. Acad. Sci. 2011, 108(18), 7535-7540. Pubmed ID: 21502504
Technical Details
| Catalog Num | A11948 |
|---|---|
| Actions | Inhibitor |
| M. Wt | 529.01 |
| Formula | C26H34ClN6O2P |
| Solubility | DMSO |
| Purity | >98% |
| Storage | at -20°C 3 years Powder |
| CAS No. | 1197958-12-5 |
| Synonyms | AP-26113 |
| SMILES | CN(C)C1CCN(CC1)C2=CC(=C(C=C2)NC3=NC=C(C(=N3)NC4=CC=CC=C4P(=O)(C)C)Cl)OC |
Datasheet
Product Tags
Product Questions
Product Questions
No Questions
Keywords:buy ALK-IN-1 (Brigatinib analog, AP26113 analog) | ALK-IN-1 (Brigatinib analog, AP26113 analog) Supplier | purchase ALK-IN-1 (Brigatinib analog, AP26113 analog) | ALK-IN-1 (Brigatinib analog, AP26113 analog) cost | ALK-IN-1 (Brigatinib analog, AP26113 analog) manufacturer | order ALK-IN-1 (Brigatinib analog, AP26113 analog) | ALK-IN-1 (Brigatinib analog, AP26113 analog) distributor | buy 1197958-12-5| 1197958-12-5 Supplier | purchase 1197958-12-5 | 1197958-12-5 cost | 1197958-12-5 manufacturer | order 1197958-12-5 | 1197958-12-5 distributor
Adooq Quality Guarantee
We promise all products perform as described.